Company / Accounts Receivable
Axsome Therapeutics, Inc. Accounts Receivable History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$224.5M
FY2025
5-year range
$37.7M / $224.5M
FY2022-FY2025
Trend
+58.1%
vs FY2024
Sector context
#32 of 113
Health Care
What the data says
At $224M, Axsome Therapeutics, Inc.'s accounts receivable ranks #32 of 113 in the Health Care sector. Accounts Receivable has increased for 3 consecutive years, from $38M in FY2022 to $224M in FY2025.
Based on SEC 10-K filings.
$224M in FY2025 with a 3-year CAGR of +81.2%.
Improved from $95M to $224M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +81.2%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#32 of 113 in Health CareTop 28% of 113This company $224.5M Sector average $1.1B
▼
-80.3% below sector average
Key checks
Key Insights
- Axsome Therapeutics, Inc.'s accounts receivable has grown for 3 consecutive years.
- 3-year CAGR of +81.2%, indicating consistent growth.
- In FY2025, accounts receivable increased 58.1% year-over-year.
- Ranks #32 out of 113 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $224.5M | +58.1% |
| FY2024 | $142.0M | +49.8% |
| FY2023 | $94.8M | +151.5% |
| FY2022 | $37.7M | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026